Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 189Neoplasm Metastasis 24Neoplasms 23Ovarian Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Breast Diseases 6Recurrence 5Medulloblastoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 4Neoplasms by Site 4Lymphoma, Mantle-Cell 4Liposarcoma 4Glioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2Fulvestrant 2tucatinib 1palbociclib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × palbociclib × Clear all
NCT04778982 2023-07-17

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated
4 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡